Trial Profile
PHASE II SAFETY AND EFFICACY STUDY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN PATIENTS WITH HIGH GRADE NON-MUSCLE INVASIVE BLADDER CARCINOMA DISEASE (NMIBC) WHO HAVE FAILED BCG AND REFUSED CYSTECTOMY
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms exBOND
- Sponsors CG Oncolgy
- 25 Mar 2020 According to a Cold Genesys media release, Cold Genesys changed its name to CG Oncology.
- 30 Jan 2019 Status changed from completed to withdrawn prior to enrolment.
- 27 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.